4-aza-4-methylpregnane-3,20-dione has been researched along with quinoxalines in 1 studies
| Studies (4-aza-4-methylpregnane-3,20-dione) | Trials (4-aza-4-methylpregnane-3,20-dione) | Recent Studies (post-2010) (4-aza-4-methylpregnane-3,20-dione) | Studies (quinoxalines) | Trials (quinoxalines) | Recent Studies (post-2010) (quinoxalines) |
|---|---|---|---|---|---|
| 5 | 0 | 0 | 9,887 | 625 | 3,095 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coenen, AM; Peeters, BW; Ramakers, GM; Vossen, JM | 1 |
1 other study(ies) available for 4-aza-4-methylpregnane-3,20-dione and quinoxalines
| Article | Year |
|---|---|
CNQX, a new non-NMDA receptor antagonist, reduces spike wave discharges in the WAG/Rij rat model of absence epilepsy.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Azasteroids; Dose-Response Relationship, Drug; Electroencephalography; Epilepsy, Absence; Female; Injections, Intraventricular; Kainic Acid; Male; N-Methylaspartate; Postural Balance; Pregnanediones; Quinoxalines; Rats; Rats, Inbred Strains; Receptors, N-Methyl-D-Aspartate | 1991 |